Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Identification of a Serotonin 2A Receptor Subtype of Schizophrenia Spectrum Disorders With Pimavanserin: The Sub-Sero Proof-of-principle Study

NCT03994965 is registered in ClinicalTrials.gov with Bjorn H. Ebdrup as lead sponsor.

NCT NCT03994965
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03994965 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Identification of a Serotonin 2A Receptor Subtype of Schizophrenia Spectrum Disorders With Pimavanserin: The Sub-Sero Proof-of-principle Study
Lead sponsor
Bjorn H. Ebdrup
Phase
Phase 2
Overall status
Withdrawn
Start date
December 1, 2024
Completion date
December 4, 2024
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

psychosis, schizophrenia